Impact of incretin-related agents on endothelial cell function

Nomoto, Hiroshi; Miyoshi, Hideaki; Nakamura, Akinobu; Atsumi, Tatsuya; Manda, Naoki; Kurihara, Yoshio; Aoki, Shin; on behalf of SAIS Study Group

Impact of incretin-related agents on endothelial cell function

Nomoto, Hiroshi; Miyoshi, Hideaki; Nakamura, Akinobu et al.

Clinical Trials in Degenerative Diseases, 2017, 2(1), 7-11

Permalink : https://hdl.handle.net/2115/67909

このアイテムのアクセス数:736件（2026-11-06 15:03 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
ClinTranslDegenerDis217-1078419_025944	pdf	300 KB	611

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/67909
タイトル	Impact of incretin-related agents on endothelial cell function
著者	Nomoto, Hiroshi ; Miyoshi, Hideaki ; Nakamura, Akinobu ; Atsumi, Tatsuya ; Manda, Naoki ; Kurihara, Yoshio ; Aoki, Shin ; on behalf of SAIS Study Group
著者名 Nomoto, Hiroshi
e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
e-Rad_Researcher 70552420 著者名 Nakamura, Akinobu
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
著者名 Manda, Naoki
著者名 Kurihara, Yoshio
著者名 Aoki, Shin
著者名 on behalf of SAIS Study Group
言語	英語
キーワード	GLP-1 analogue
	DPP-4 inhibitor
	endothelial cell function
発行日	2017-01
出版者	Wolters Kluwer
収録物名	Clinical Trials in Degenerative Diseases
巻(号)	2(1)
ページ	7-11
抄録	Incretin-related drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, have been clinically available and widely used to treat patients with type 2 diabetes mellitus. Accumulating evidence indicates that these agents exert glycemic control and have various other favorable effects, including prevention of atherosclerosis. It is important to assess and manage early-phase atherosclerosis, but whether diabetic therapeutics including incretin-related drugs improve or maintain vascular endothelial cell function has not been fully determined. We previously published prospective clinical trials focused on flow-mediated dilation in patients with type 2 diabetes, who did not have severe atherosclerosis, using two different incretin-related drugs: a DPP-4 inhibitor and a GLP-1 analogue. These trials showed that these therapeutic agents did not improve endothelial cell function. In this article, we discuss how incretin-related drugs contribute, if at all, to vascular endothelial cell function, atherosclerosis, and beta-cell function, based on our clinical trials and previous evidence.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported
PISSN	2542-3975
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.4103/2542-3975.202726